ViiV Healthcare showcases long-acting HIV innovation and potential of ultra long-acting pipeline, including new data for first third-generation integrase inhibitor at CROI 2026
Pfizer, Inc. (PFE)
Last pfizer, inc. earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.pfizer.com/investors-overview/default.aspx
Company Research
Source: Business Wire
First-in-human data for long-acting formulations of VH184, the first third-generation integrase inhibitor, and early data for capsid inhibitor VH499 to be presented, highlighting progress in ViiV’s ultra long-acting pipeline12-month data to be presented for investigational lotivibart (N6LS) + cabotegravir long-acting, evaluating feasibility of ultra long-acting dosing intervalsClinical data and real-world evidence from ViiV’s innovative portfolio include insights for established INSTI-based long-acting Cabenuva (cabotegravir + rilpivirine LA) and 2-drug regimen Dovato (dolutegravir/lamivudine) LONDON--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders,* today announced data presentations from its innovative HIV treatment and prevention portfolio and integrase inhibitor (INSTI)-led pipeline at the 33rd Conference on Retroviruses and Opportunistic Infections (CROI) in Denver, Colorado from 22-25 February
Show less
Read more
Impact Snapshot
Event Time:
PFE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PFE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PFE alerts
High impacting Pfizer, Inc. news events
Weekly update
A roundup of the hottest topics
PFE
News
- ViiV Healthcare’s long-acting Cabenuva (cabotegravir + rilpivirine) for HIV demonstrates superior efficacy compared to daily oral therapy for people with adherence challenges; results published in NEJMBusiness Wire
- Pfizer: Recovery Isn't Over, Battered Valuation Still Discounts Its Turnaround Game [Seeking Alpha]Seeking Alpha
- Pfizer: The Rebound Looks Unsustainable [Seeking Alpha]Seeking Alpha
- Pfizer’s BRAFTOVI Regimen Improves Progression-Free Survival in Metastatic Colorectal CancerBusiness Wire
- Pfizer (NYSE:PFE) was downgraded by analysts at Daiwa America from a "strong-buy" rating to a "hold" rating.MarketBeat
PFE
Earnings
- 2/3/26 - Beat
PFE
Sec Filings
- 2/17/26 - Form 4
- 2/12/26 - Form 13F-HR
- 2/3/26 - Form 8-K
- PFE's page on the SEC website